BrightGene Bio Medical Technology C Tangible Net Worth Ratio
BrightGene Bio Medical Technology C tangible net worth ratio. BrightGene Bio Medical Technology C (688166) has a Tangible Net Worth Ratio of 88.0% as of June 2025. This metric is calculated by deducting intangible assets (CN¥311.28 Million) from net assets (CN¥2.59 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset growth rate of BrightGene Bio Medical Technology C to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of BrightGene Bio Medical Technology C (2016–2024)
Tangible net worth ratio of BrightGene Bio Medical Technology C from 2016 to 2024. This chart shows how BrightGene Bio Medical Technology C's Tangible Net Worth Ratio has changed across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 88.0%, reflecting net assets of CN¥2.59 Billion with intangible assets of CN¥311.28 Million CNY. Check BrightGene Bio Medical Technology C PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
BrightGene Bio Medical Technology C Tangible Net Worth Ratio by Year (2016–2024)
BrightGene Bio Medical Technology C tangible net worth ratio by year from 2016 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 688166 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 95.7% | CN¥2.44 Billion | CN¥103.82 Million | CN¥5.16 Billion | ▼ -0.4 pp |
| 2023 | 96.1% | CN¥2.42 Billion | CN¥93.66 Million | CN¥5.03 Billion | ▼ -0.2 pp |
| 2022 | 96.4% | CN¥2.24 Billion | CN¥81.64 Million | CN¥4.66 Billion | ▲ +1.0 pp |
| 2021 | 95.4% | CN¥1.74 Billion | CN¥80.84 Million | CN¥2.97 Billion | ▼ -1.2 pp |
| 2020 | 96.6% | CN¥1.43 Billion | CN¥48.76 Million | CN¥1.83 Billion | ▼ -3.0 pp |
| 2019 | 99.6% | CN¥1.31 Billion | CN¥5.81 Million | CN¥1.42 Billion | ▲ +0.2 pp |
| 2018 | 99.3% | CN¥772.85 Million | CN¥5.05 Million | CN¥878.37 Million | ▲ +1.2 pp |
| 2017 | 98.1% | CN¥446.02 Million | CN¥8.31 Million | CN¥524.92 Million | ▲ +1.9 pp |
| 2016 | 96.3% | CN¥220.15 Million | CN¥8.18 Million | CN¥384.19 Million | — |